Interestingly, in a study by Kooistra et al. on patients with COVID-19, it was shown that immunomodulatory treatment with dexamethasone and tocilizumab considerably reduced the value of procalcitonin and CRP for detection of secondary infections in COVID-19 patients [23]. This evidence concerns the gene CRP and COVID-19.